These functions of the protein-based cGAS-STING nanoagonist in the present study could act in a cooperative manner to enhance the DC-mediated cross-priming of antitumor effector T cells in TME and improve antitumor immune responses in poorly immunogenic tumor models, which provides emerging opportunities for enhancing the efficacy of immunotherapies against solid tumor indications in the clinics. Here, STING1 is linked to neoplasm.